Chemotherapy in the treatment of metastatic gastric cancer: Is There a global standard?

Hyunseok Kang, John S. Kauh

Research output: Contribution to journalArticlepeer-review

Abstract

Gastric cancer remains one of the leading causes of cancer mortality worldwide even though its incidence has been decreasing in recent years. Despite remarkable advancements in chemotherapy, advanced gastric cancer has remained a therapeutic challenge for physicians as well as for patients. While early chemotherapeutic regimens succeeded in showing a modest but definite improvement over best supportive care, no single regimen stood out as superior. Most early trials failed to show survival benefit of combination regimens over single agent fluorouracil, but combination regimens were shown to have better response rates. Based on these data, the Japanese adopted single agent fluorouracil as a reference standard for further investigations, while the rest of the world used a doublet containing fluorouracil and platinum. As more clinical trials were conducted, the Japanese standard evolved into a doublet, while the Western countries adopted triplet combinations. There is no established global standard as yet, but with the introduction of newer targeted agents based on molecular assays and personalized approaches combined with conventional chemotherapy, multiple regimens are likely to emerge as global standards rather than one standard treatment for all.

Original languageEnglish (US)
Pages (from-to)96-106
Number of pages11
JournalCurrent treatment options in oncology
Volume12
Issue number1
DOIs
StatePublished - Mar 1 2011

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Chemotherapy in the treatment of metastatic gastric cancer: Is There a global standard?'. Together they form a unique fingerprint.

Cite this